3.4 Cardiac MRI and CT in cardiology for evaluation

SadanandIndi 56 views 59 slides Jun 20, 2024
Slide 1
Slide 1 of 59
Slide 1
1
Slide 2
2
Slide 3
3
Slide 4
4
Slide 5
5
Slide 6
6
Slide 7
7
Slide 8
8
Slide 9
9
Slide 10
10
Slide 11
11
Slide 12
12
Slide 13
13
Slide 14
14
Slide 15
15
Slide 16
16
Slide 17
17
Slide 18
18
Slide 19
19
Slide 20
20
Slide 21
21
Slide 22
22
Slide 23
23
Slide 24
24
Slide 25
25
Slide 26
26
Slide 27
27
Slide 28
28
Slide 29
29
Slide 30
30
Slide 31
31
Slide 32
32
Slide 33
33
Slide 34
34
Slide 35
35
Slide 36
36
Slide 37
37
Slide 38
38
Slide 39
39
Slide 40
40
Slide 41
41
Slide 42
42
Slide 43
43
Slide 44
44
Slide 45
45
Slide 46
46
Slide 47
47
Slide 48
48
Slide 49
49
Slide 50
50
Slide 51
51
Slide 52
52
Slide 53
53
Slide 54
54
Slide 55
55
Slide 56
56
Slide 57
57
Slide 58
58
Slide 59
59

About This Presentation

Cardiology#invstigation


Slide Content

Cardiac MRI and CT

Dr Venugopal K. MD DM
Professor &HOD Cardiology
Pushpagiri Institute of Medical Sciences
Tiruvalla

Feature

lonising radiation
Optimal window
Availability

Cost

Portability

Great Vessel imaging

Soft Tissue evaluation

Fat, blood, water,
distinction

Multiplanar imaging

Initial patient
evaluation

Duration
Claustrophobia

Prosthetic materials

MRI

No

No
Variable
Expensive
No

Excellent

Excellent

Excellent

Yes

Lilimited

30- 60 mts
Not possible

With Caution

CT

Yes

No
Wide
Cheaper
No

Excellent

Good

Fair

No

Yes

Few mts
Possible

Possible

Cautions with MRI

Contraindications

Ferro magnetic aneurysm clips

Metallic fragments in eyes or other vital areas
Pacemakers (MRI incompatible)

ICDS

Prosthetic valves (SE Ball and cage Valves)
Insulin pumps

Neural stimulators

Sternal wires , Stents not contraindicated

Gadolinium Nephrogenic systemic fibrosis
Not advised in pts with GFR <30 ml /m2

Cardiac Magnetic Resonance (CMR) allows the simultaneous
visualization of both cardiac function and anatomy.

Quantify coronary blood flow in coronary artery disease

Accurately measure left and right ventricular volumes, ventricular
wall thickness, mass, and diameters of the great vessels

Characterize myocardial viability
Quantify myocardial infarction size
Measure blood flow in the myocardium as well as the great vessels

CMR is considered the “gold” standard for noninvasively
characterizing cardiac function and viability, having 3D capabilities
and a high spatial resolution.

Imaging sequences are gated using a 3-lead ECG.
Typically, ventricular cines are imaged with 12-25 phases
spanning the cardiac cycle.

Ventricular cines in either the cardiac short-axis or long-
axis can provide an accurate estimation of the following
functional parameters:

Ejection fraction (EF)
Systolic wall thickening
Wall motion

+ Delayed contrast enhancement using gadolinium
is the preferred method to identify a scarred
region caused by a chronic myocardial infarction.

« Signal enhancement in scarred regions will occur
approximately 5 minutes after the initial contrast
bolus.

* Scarred regions will retain the contrast agent as
cell death and tissue edema (which occur after an
infarction and subsequent scarring) alter the
wash-in and wash-out kinetics of the extracellular
contrast agent.

+ CMR flow imaging has been useful in the
diagnosis of valvular regurgitation, aortic
stenosis, and has even been used for
angiography.

Indications

Coronary artery disease

A. Assessment of global ventricular function and
mass

B. Detection of CAD

i. Regional LV function at rest and during
dobutamine stress

ii. Assessment of myocardial perfusion
(adenosine stress)

iii. Coronary MRA (anomalies)

C. Acute and chronic myocardial infarction
i. Detection and assessment
ii. Myocardial viability

+ Cardiomyopathies

. A. Hypertrophic cardiomyopathy

. B. Dilated cardiomyopathy

. C. Arrhythmogenic Right Ventricular
Cardiomyopathy

. D. Restrictive cardiomyopathies

. i. Sarcoid

. ii. Amyloid

. iii. Eosinophilic

. E. Myocarditis

Cardiac and pericardiac masses
A. Primary cardiac
B. Pericardiac (including pericardial)
C. Thrombus
Pericardial disease
A. Pericardial effusion
B. Constrictive pericarditis

Valvular heart disease
A. Quantification of regurgitation
Congenital heart disease (CHD)
A. Assessment of shunt size
B. Anomalous pulmonary venous return
C. Ebstein's anomaly
D. Pulmonary regurgitation
E. Atrial septal defect
Diseases of the aorta and great vessels
A. Aortic aneurysm
B. Aortic dissection
C. Intramural hematoma

Ischemic

Idiopathic DCM —
Basal mid-wall

HCM - patchy, intraseptal

Subendocardial infarct

Transmural infarct

ARVD, DELAYED ENHANCEMENT

30-80% of (advanced) cases have LV, as well as RV enhancement /

Amyloidosis

Thickened Pericardium in Constrictive
pericarditis

Hypertrophic cardiomyopathy

Apical HCM

RVEMF with Right atrial Thrombus

Delayed contrast enhancement Delayed contrast enhancement
Showing RV apical hyper With TI (inversion time) 600 to
enhancement identify thrombus

Thrombus seen as black

IWMI

NON viable territory

Viable territory

Post icr rv enlargement

Pulmonary atresia, MAPCA

Classical BT shunt

ı = =.
y = à
'

Septal bounce

Image size: 448 x 448
View size 1199 x 1199
WL: 770 WW: 1066

Zoom: 268% Angle

Uncompresses

10229464 ( 36y, 31y)
154_cor_highres ~ RADIAL

29]

Cardiac CT

Calcium Score

0

1-10
11-100
101-400
Over 400

Presence of CAD

No evidence of CAD
Minimal evidence of CAD
Mild evidence of CAD
Moderate evidence of CAD
Extensive evidence of CAD

VENKATESHLD
15673 Mí38Y

TO1-1 VR

c

Philips, Brillance 64 VENKATESH.LD
9 Nov, 2016 15015700 45673 Muay

2108 701-2VR


Philips, Brillance 64
9 Nov, 2016 1501:47.00
2103

VENKTAMMA

Jon 20
VENKTAMMA
16135 F/6SY
5750%

c

JAYADEVA TRINITY CT

OEVA TRINITY CT | VENKTAMMA ilps, Briliance 64

lips, Brillance 64 46135 654 jan, 2017 13541200

fon, 201713540200 5056725 VR 2200
220 €

RAJU
15938 Nv6BY
907-1 VR

c

Brillance 61 RAJU
1611932700 15038 68
ZUM 907-2VR

Occluded RIMA 3%,

SG Stump 3

He

/ Occluded-
RC + f RIMA

Philips, Brilliance 61 SARANYA |
28 Nov, 2016 12284400 45630 F

Cc

prov 3800 nil

Puso

219

tance 6 YASHODA lance 64
29 Dec, 2016 15394200 1609 F/26Y 016 1539420
2135 sossi-2 VR 7135

c

SHANKARAPPA PIS, Briliance 64 SHANKARAPPA Philips, Brilliance 64

15000 MY 24Nov, 201613510000 45 24 Nov, 2016 13510000
50522-3VR 2100 2100

c

sortie DILATATION

MANDALAL

wer a . y T Philips, Brilliance 64
5, Brilliance 64 NANDALAL y 19 Nov, 2016 55340.00
Mage To Fe Et y 4
2156 701-5VR a P «
E

TAKSHMT'S
e i a Brilliance 64

Philips, Brilliance 64 LAKSHMI S K Philips, Brillanc
ee a 4 Nov, 2016 16:37:02.00 45639 F/65V 4 Nov, 2016 16:37: E me
50522-1 VR 2136 5522-3 VR

c 12

GANGAMMA
15698 F165"
0582-3 VR

3

Philips, Brillance 61 GANGAMMA
12 Nov, 2016 1494500 45608 F/65Y

2100 50582-4 VR
c

20cm

Philips, Briliance 64
12 Nov, 2016 13344500
2100

THANK YOU
Tags